# OnCo record anti-gd2-plus-chemo-relapse (pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pairings/anti-gd2-plus-chemo-relapse/>
  a schema:MedicalTherapy ;
  onco:kind "pairing" ;
  schema:identifier "anti-gd2-plus-chemo-relapse" ;
  schema:name "Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)"@en ;
  schema:description "Adding the anti-GD2 antibody to relapse chemotherapy doubled response rates in relapsed neuroblastoma, and the idea is now moving into first-line induction."@en ;
  schema:url <https://onco.cc/pairings/anti-gd2-plus-chemo-relapse/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30355-8> ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:targets <https://onco.cc/targets/gd2/> ;
  onco:drugs <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/naxitamab/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:pairs <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/temozolomide/> .